Zacks: Brokerages Anticipate Colgate-Palmolive (NYSE:CL) to Post $0.71 EPS

Wall Street analysts forecast that Colgate-Palmolive (NYSE:CL) will announce earnings of $0.71 per share for the current quarter, according to Zacks. Six analysts have made estimates for Colgate-Palmolive’s earnings, with the highest EPS estimate coming in at $0.71 and the lowest estimate coming in at $0.70. Colgate-Palmolive posted earnings of $0.72 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 1.4%. The firm is expected to announce its next earnings report on Friday, October 25th.

On average, analysts expect that Colgate-Palmolive will report full-year earnings of $2.84 per share for the current fiscal year, with EPS estimates ranging from $2.83 to $2.85. For the next financial year, analysts expect that the company will report earnings of $3.06 per share, with EPS estimates ranging from $3.00 to $3.13. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Colgate-Palmolive.

Colgate-Palmolive (NYSE:CL) last posted its quarterly earnings data on Friday, July 26th. The company reported $0.72 EPS for the quarter, hitting the Zacks’ consensus estimate of $0.72. Colgate-Palmolive had a net margin of 14.77% and a negative return on equity of 10,821.98%. The company had revenue of $3.87 billion during the quarter, compared to the consensus estimate of $3.88 billion. During the same period in the prior year, the business posted $0.77 EPS. The company’s quarterly revenue was down .5% on a year-over-year basis.

A number of research firms have recently commented on CL. ValuEngine upgraded shares of Colgate-Palmolive from a “hold” rating to a “buy” rating in a research note on Monday, May 13th. Zacks Investment Research downgraded shares of Colgate-Palmolive from a “buy” rating to a “hold” rating and set a $77.00 price target for the company. in a research note on Friday, June 7th. Argus raised their price target on shares of Colgate-Palmolive from $72.00 to $82.00 and gave the company a “buy” rating in a research note on Tuesday, June 11th. JPMorgan Chase & Co. raised shares of Colgate-Palmolive from an “underweight” rating to a “neutral” rating and raised their price target for the company from $62.00 to $70.00 in a research note on Monday, April 29th. Finally, Deutsche Bank raised their price target on shares of Colgate-Palmolive from $74.00 to $76.00 and gave the company a “hold” rating in a research note on Friday, July 12th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $73.13.

Shares of Colgate-Palmolive stock traded up $0.28 during trading hours on Thursday, reaching $72.02. 147,852 shares of the company’s stock were exchanged, compared to its average volume of 3,012,884. The business’s 50 day moving average is $73.19. Colgate-Palmolive has a fifty-two week low of $57.41 and a fifty-two week high of $76.41. The company has a current ratio of 1.13, a quick ratio of 0.78 and a debt-to-equity ratio of 32.25. The firm has a market cap of $61.56 billion, a PE ratio of 24.27, a P/E/G ratio of 4.93 and a beta of 0.78.

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Investors of record on Thursday, July 18th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date of this dividend is Wednesday, July 17th. Colgate-Palmolive’s dividend payout ratio is presently 57.91%.

In other Colgate-Palmolive news, insider Ian M. Cook sold 19,500 shares of Colgate-Palmolive stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $69.92, for a total value of $1,363,440.00. Following the completion of the sale, the insider now directly owns 1,186,042 shares of the company’s stock, valued at $82,928,056.64. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Justin Skala sold 92,643 shares of Colgate-Palmolive stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $70.78, for a total transaction of $6,557,271.54. Following the completion of the sale, the vice president now directly owns 163,653 shares of the company’s stock, valued at $11,583,359.34. The disclosure for this sale can be found here. Insiders have sold 213,455 shares of company stock valued at $15,233,388 in the last three months. 1.14% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of CL. Meridian Wealth Management LLC acquired a new position in shares of Colgate-Palmolive during the first quarter valued at about $29,000. Lipe & Dalton acquired a new position in shares of Colgate-Palmolive during the second quarter valued at about $29,000. WP Advisors LLC acquired a new position in shares of Colgate-Palmolive during the first quarter valued at about $34,000. Princeton Global Asset Management LLC acquired a new position in shares of Colgate-Palmolive during the first quarter valued at about $43,000. Finally, Paragon Capital Management LLC acquired a new position in shares of Colgate-Palmolive during the first quarter valued at about $46,000. 75.52% of the stock is owned by hedge funds and other institutional investors.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. It offers oral care products, including toothpastes, toothbrushes, and mouthwashes, as well as pharmaceutical products for dentists and other oral health professionals; and personal care products, such as liquid hand soaps, bar soaps, shower gels, deodorants and antiperspirants, skin care products, and shampoos and conditioners.

Further Reading: Different Types of Derivatives

Get a free copy of the Zacks research report on Colgate-Palmolive (CL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Colgate-Palmolive (NYSE:CL)

Receive News & Ratings for Colgate-Palmolive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Colgate-Palmolive and related companies with MarketBeat.com's FREE daily email newsletter.